Clinical trials: Breast Atypical Hyperplasia
Breast Cancer
Women At Risk: The High Risk Breast Cancer Program
The purpose of this study is to increase understanding of women who are at high risk for developing breast cancer. Data from this group will be collected and entered into a registry.
- Trial name
- WAR (NCT01034891)
- Where
- 2 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- New York Presbyterian Hospital
Breast Cancer
FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments
Electronic health records (EHRs) are an increasingly common source for populating risk models, but whether used to populate validated risk assessment models or to de-facto build risk prediction models, EHR data presents several…
- Trial name
- FHIR (NCT05810025)
- Testing
- RealRisks
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Columbia University
Breast Cancer, Precancerous Condition
Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia
RATIONALE: Polyunsaturated fatty acids are important for normal growth and development. One type, called omega-3 fatty acids (found in fish, fish oil, and some other foods), may affect the growth of abnormal breast cells.
- Trial name
- NCT00627276
- Testing
- omega-3 fatty acid
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identify modifiable risk factors, screen high risk patients early, improve…
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05178498
- Testing
- Follow-Up, Physical Examination, Questionnaire Administration
- Where
- United States
- Volunteers
- 960 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer, Precancerous Condition
Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy
RATIONALE: Broccoli sprout extract supplements may slow the growth of tumor cells or abnormal cells and may be an effective treatment for ductal carcinoma in situ and/or atypical ductal hyperplasia.
- Trial name
- NCT00843167
- Testing
- broccoli sprout extract
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
Markers for Breast Cancer
This study will analyze blood samples to identify substances that are associated with the development of breast cancer. It will determine if: Women who are diagnosed with a benign breast condition that is related to a…
- Trial name
- NCT00339248
- Where
- United States
- Volunteers
- 2,632 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer
To assess the quantitative real time PCR results results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors of indicators of response to celecoxib.
- Trial name
- NCT00291122
- Testing
- celecoxib 400 mg BID
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Kansas
Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers.
- Conditions
- Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
- Trial name
- NCT04496739
- Testing
- Cancer Educational Materials, Decision Aid, Interview
- Where
- 97 sites in United States, Guam
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- SWOG Cancer Research Network
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia
Ruxolitinib for Premalignant Breast Disease
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for…
- Conditions
- Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
- Trial name
- TBCRC042 (NCT02928978)
- Testing
- Ruxolitinib
- Where
- 8 sites in United States
- Volunteers
- 84 people
- Sponsor
- Julie Nangia
Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia
Molecular Breast Imaging in Women With Atypia and LCIS
We aim to determine if Molecular Breast Imaging (a new nuclear medicine technique developed at Mayo) can identify malignant breast lesions in women who have atypical ductal hyperplasia, atypical lobular hyperplasia, or lobular…
- Conditions
- Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
- Trial name
- NCT00620087
- Testing
- Molecular Breast Imaging, Screening Mammography
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer, Invasive Carcinoma
X-Ray Mammography Standard of Care Protocol
Background: X-ray mammography is the standard method for breast cancer screening. It is a noninvasive test using x-rays to take pictures of breast tissue and detect any abnormalities.
- Conditions
- Breast Cancer, Invasive Carcinoma, In Situ Carcinoma, Fibrocystic Changes
- Trial name
- NCT01052740
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS)
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) increases breast cancer risk. In post menopausal women, SERMS are standard chemopreventive agents.
- Conditions
- Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast
- Trial name
- NCT01372644
- Testing
- SOM 230 / Pasireotide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Ductal Carcinoma in Situ of the Breast
Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment Trial
This study aims to evaluate the 5-year invasive ipsilateral breast cancer incidence rate in patients with hormone-receptor positive, HER-2 negative atypical ductal hyperplasia or in-situ carcimona who omitted surgery and received…
- Trial name
- ASAIN (NCT07245316)
- Testing
- Avoiding surgery
- Where
- South Korea
- Volunteers
- 340 people
- Sponsor
- Jeong Eon Lee
Breast Cancer
Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
A study to examine the potential associations between common single nucleotide polymorphisms and pre-cancerous conditions in breast tissue specimens from postmenopausal women.
- Trial name
- NCT00329017
- Testing
- Fine needle aspiration
- Where
- United States
- Sponsor
- Carol Fabian, MD
Breast Cancer, Precancerous Condition
Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer
RATIONALE: Ground flaxseed may prevent breast cancer in premenopausal women at increased risk of developing primary breast cancer.
- Trial name
- NCT00794989
- Testing
- Ground Flaxseed, No Intervention
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Endometrial Cancer, Endometrial Hyperplasia With Atypia
Endometrial Changes in Breast Cancer Women.
This is a prospective observational multicentric study. The aim is to evaluate the incidence of endometrial cancer and endometrial atypical hyperplasia in patients with previous breast cancer, treated with different adjuvant…
- Conditions
- Endometrial Cancer, Endometrial Hyperplasia With Atypia, Breast Cancer, TAM
- Trial name
- NCT05717634
- Testing
- Hysteroscopy
- Where
- Italy
- Volunteers
- 829 people, healthy volunteers welcome
- Sponsor
- Regina Elena Cancer Institute
Atypical Ductal Hyperplasia (ADH) of the Breast
Atypical Lesions of the Breast: Close Observation Versus Excision (ALCOVE)
This study is designed to look at whether it is feasible to observe women with atypical ductal hyperplasia (ADH) of the breast, or whether surgical excision is necessary.
- Trial name
- ALCOVE (NCT01925586)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Yale University
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT03323658
- Testing
- Bexarotene, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg
To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to letrozole
- Trial name
- NCT00291109
- Testing
- letrozole 2.5 mg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Kansas
Breast Cancer
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
The overall goal of this project is to determine if high dose vitamin D3 given to premenopausal women at high risk for development of breast cancer, who initially have insufficient levels of 25-hydroxy vitamin D (<30 ng/ml), will…
- Trial name
- NCT01166763
- Testing
- vitamin D3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Carol Fabian, MD